Liver Cirrhosis Treatment Market Size, Share, World Report, Covid 19 Impact Analysis by 2027

 Liver Cirrhosis Treatment Market Research Report: By Treatment (Antibiotics, Immunosuppressants) and End-User (Hospitals and Clinics, Research and Academic Institutes) – Forecast to 2027

According to MRFR analysis, the global liver cirrhosis treatment market is expected to register a CAGR of ~5.2% during the forecast period of 2019 to 2025 and was valued at USD 956.89 million in 2018.

Free sample copy  @https: //www.marketresearchfuture.com/sample_request/8367

Regional analysis

The market is divided by region into the Americas, Europe, Asia Pacific, and the Middle East / Africa. The Americas are expected to become the largest market due to the prevalence of cirrhosis and the growing population of the elderly. The cirrhosis treatment market in the Americas is further divided into North America and Latin America, and the North American market is divided into the United States and Canada. The European cirrhosis treatment market is divided into Western Europe and Eastern Europe. The Western European market is further subdivided into Germany, France, the United Kingdom, Italy, Spain, and the rest of Western Europe. The Asia Pacific cirrhosis treatment market is divided into Japan, China, India, South Korea, Australia and other Asia Pacific regions. The Asia Pacific market is expected to grow the fastest as the pool of patients with cirrhosis grows and awareness of the disease increases. The Middle East / Africa cirrhosis treatment market is divided into the Middle East and Africa.

segmentation

The global Liver Cirrhosis Treatment Market is segmented based on treatment and end user.

The global cirrhosis treatment market is segmented into antibiotics, immunosuppressants, etc. based on the treatment. The antibiotic segment is expected to occupy most of the market as antibiotics are the most preferred type of prescription drug for patients with cirrhosis due to the high risk of infection. The immunosuppressive agent segment is expected to grow at the fastest CAGR due to increased liver transplantation. Until October 2017, there were 147,842 liver transplants in the Americas. Immunosuppressants are a type of drug prescribed to patients who have undergone a liver transplant to reduce the risk of organ rejection. Other treatment options include drugs that lower ammonia levels, antihypertensive drugs, and drugs that lower blood pressure.

End-user-based markets are categorized into hospitals, clinics, research institutes, academic institutions, and more. The hospital and clinic segments are expected to have the largest share of the market as they are the main centers of patient care. Research and academic institutions are conducting research activities to develop new treatments for cirrhosis. Other end users include home care settings and specific centers for the treatment of the elderly.

Main players

Some of the major players in the global liver cirrhosis treatment market are Pfizer, Inc. (USA), Merck & Co. (Germany), Novartis AG (Switzerland), F. Hoffman La Roche (Switzerland), Takeda Pharmaceutical Companies Co., Ltd. (Japan), Gilead Sciences (US), AstraZeneca (UK), Bayer AG (Germany), Sanofi (France), Shionogi (Japan), Promesera (Belgium)

Full report details @  https://www.marketresearchfuture.com/reports/liver-cirrhosis-treatment-market-8367

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.